EA201290069A1 - Модифицированные полипептиды фактора ix и их применения - Google Patents

Модифицированные полипептиды фактора ix и их применения

Info

Publication number
EA201290069A1
EA201290069A1 EA201290069A EA201290069A EA201290069A1 EA 201290069 A1 EA201290069 A1 EA 201290069A1 EA 201290069 A EA201290069 A EA 201290069A EA 201290069 A EA201290069 A EA 201290069A EA 201290069 A1 EA201290069 A1 EA 201290069A1
Authority
EA
Eurasian Patent Office
Prior art keywords
factor
application
polypeptide
modified polypeptides
modified factor
Prior art date
Application number
EA201290069A
Other languages
English (en)
Russian (ru)
Inventor
Элэн Брукс
Чендра Пэтель
Щиаокиао Жианг
Увэ Гритцан
Хайнер Апелер
Джун Ванг
Original Assignee
Байер Хелскер Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201290069(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Хелскер Ллс filed Critical Байер Хелскер Ллс
Publication of EA201290069A1 publication Critical patent/EA201290069A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA201290069A 2009-07-31 2010-08-02 Модифицированные полипептиды фактора ix и их применения EA201290069A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
EA201290069A1 true EA201290069A1 (ru) 2012-07-30

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290069A EA201290069A1 (ru) 2009-07-31 2010-08-02 Модифицированные полипептиды фактора ix и их применения

Country Status (21)

Country Link
US (1) US20120164130A1 (https=)
EP (1) EP2461821A4 (https=)
JP (1) JP2013500726A (https=)
KR (1) KR20120060209A (https=)
CN (1) CN102573890A (https=)
AU (1) AU2010278721A1 (https=)
BR (1) BR112012002072A2 (https=)
CA (1) CA2769258A1 (https=)
CL (1) CL2012000238A1 (https=)
CR (1) CR20120052A (https=)
CU (3) CU20120018A7 (https=)
DO (1) DOP2012000030A (https=)
EA (1) EA201290069A1 (https=)
EC (1) ECSP12011637A (https=)
GT (1) GT201200023A (https=)
IN (1) IN2012DN00908A (https=)
MX (1) MX2012001346A (https=)
PE (1) PE20121643A1 (https=)
SG (1) SG178119A1 (https=)
WO (1) WO2011014890A1 (https=)
ZA (1) ZA201200716B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
TR201813067T4 (tr) 2008-09-15 2018-09-21 Uniqure Biopharma B V Faktör IX polipeptit mutantı, bunun kullanımları ve bunu üretmeye yönelik bir yöntem.
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
TR201908836T4 (tr) * 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
RU2617764C2 (ru) * 2011-12-19 2017-04-26 Дилафор Аб Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение
CA2892038C (en) * 2012-11-20 2021-12-28 Darrel W. Stafford Methods and compositions for modified factor ix proteins
US10105447B2 (en) * 2013-03-13 2018-10-23 Elanco Us Inc. Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
CN109789181A (zh) * 2016-07-27 2019-05-21 费城儿童医院 用于调节因子ix功能的组合物和方法
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
AU2019360270B2 (en) 2018-10-18 2025-08-07 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044982A1 (en) * 2001-04-25 2003-03-06 Kenneth Chien Method to treat hemophilia by hepatic gene transfer of factor VIII/IX with vesicle vector
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
MXPA06006023A (es) * 2003-12-03 2006-08-23 Neose Technologies Inc Factor ix glicopegilado.
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
CU20120018A7 (es) 2012-06-21
MX2012001346A (es) 2012-02-17
EP2461821A4 (en) 2013-07-03
CU20130058A7 (es) 2013-06-28
BR112012002072A2 (pt) 2016-11-08
ECSP12011637A (es) 2012-02-29
CN102573890A (zh) 2012-07-11
WO2011014890A1 (en) 2011-02-03
CR20120052A (es) 2012-06-04
CU20130057A7 (es) 2013-06-28
JP2013500726A (ja) 2013-01-10
GT201200023A (es) 2014-01-27
EP2461821A1 (en) 2012-06-13
ZA201200716B (en) 2013-07-31
SG178119A1 (en) 2012-03-29
US20120164130A1 (en) 2012-06-28
DOP2012000030A (es) 2012-02-29
IN2012DN00908A (https=) 2015-04-03
CA2769258A1 (en) 2011-02-03
AU2010278721A1 (en) 2012-02-16
PE20121643A1 (es) 2012-11-25
CL2012000238A1 (es) 2012-10-05
KR20120060209A (ko) 2012-06-11

Similar Documents

Publication Publication Date Title
EA201290069A1 (ru) Модифицированные полипептиды фактора ix и их применения
UA106586C2 (uk) Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
EA201790876A1 (ru) Способ контроля, предотвращения или лечения кровотечения
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
EA201290557A1 (ru) Пептидный аналог оксинтомодулина
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EA201490039A1 (ru) Химерные и гибридные полипептиды фактора viii и способы их применения
MX358739B (es) Proteinas de union a amiloide beta.
MX382826B (es) Anticuerpos dkk1 y metodos de uso.
EP2571503A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASES AND OTHER CONDITIONS
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
EA201391000A1 (ru) Индольные соединения или их аналоги, полезные для лечения возрастной макулярной дегенерации (amd)
EA201490195A1 (ru) Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
MX342920B (es) Metodo para purificar polipeptidos o inmunoconjugados activos.
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EA201100072A1 (ru) Новые композиции и способы
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения
EA201290322A1 (ru) Лечение желудочно-кишечных расстройств
EA201291065A1 (ru) Антитела против vla-4
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора